1) Watanabe O:Neuroimmunological diseases associated with VGKC complex antibodies. Nihon Rinsho 2016;71:915-20 (in Japanese) 2) Padmanabhan A, Connelly-Smith L, Aqui N, et al:Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the Writing Committee of the American Society for Apheresis:The eighth special issue. J Clin Apher 2019;34:171-354 3) Dubey D, Samudra N, Gupta P, et al:Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure 2015;29:143-7 4) Heine J, Ly LT, Lieker I, et al:Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis:a pilot study. J Neurol 2016;263:2395-402 5) Dogan-Onugoren M, Golombeck KS, Bien C, et al:Immunoasorption therapy in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2016;3:e207 6) Irani SR, Gelfand JM, Bettcher BM, et al:Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibodyassociated encephalopathy. JAMA Neurol 2014;71:896-900 7) Wong SH, Saunders MD, Larner AJ, et al:An effective immunotherapy regimen for VGKC antibody positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010;81:1167-9 8) Vincent A, Buckley C, Schott JM, et al:Potassium channel antibodyassociated encephalopathy:a potentially immunotherapy-responsive form oflimbic encephalitis. Brain 2004;127:701-12 9) Jaben EA, Winters JL:Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels:a report of five cases and review of the literature. J Clin Apher 2012;27:267-73
